Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: Nested cohort within a multicenter clinical trial

Jiro Fujita, Yoshihito Niki, Jun Ichi Kadota, Katsunori Yanagihara, Mitsuo Kaku, Akira Watanabe, Nobuki Aoki, Seiji Hori, Yusuke Tanigawara, Haley L. Cash, Shigeru Kohno

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We evaluated the clinical and bacteriological efficacy of oral sitafloxacin (STFX) in clinically diagnosed community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. Additionally, we cultured these patient samples to test the minimal inhibitory concentrations (MICs) of levofloxacin (LVFX), moxifloxacin (MFLX), STFX, and penicillin G (PCG), as well as identified mutations in the quinolone resistance determinant regions (QRDRs) in LVFX-resistant strains. This study is a nested cohort from a prospective, multicenter clinical trial consisting of 139 patients with community-acquired pneumonia (CAP), from which 72 were included in this study. After diagnosis of CAP caused by S. pneumoniae, STFX (50 mg twice daily, or 100 mg once daily) was orally administered for 7 days. Sixty-five patient sputum samples were then cultured for MIC analysis. In a LVFX-resistant strain that was identified, mutations in the QRDRs of the gyrA, gyrB, parC, and parE genes were examined. Of 72 patients eligible for this study, S. pneumoniae was successfully cultured from the sputum of 65 patients, and only 7 patients were diagnosed by urinary antigen only. Clinical improvement of CAP was obtained in 65 of the 69 clinically evaluable patients (65/69, 94.2 %). Eradication of S. pneumoniae was observed in 62 patients of the 65 bacteriologically evaluable patients (62/65, 95.4 %). Additionally, STFX showed the lowest MIC distribution compared with LVFX, MFLX, and PCG, and no major adverse reactions were observed. STFX treatment in patients with CAP caused by S. pneumoniae was found to be highly effective both clinically (94.2 %) and bacteriologically (95.4 %).

Original languageEnglish
Pages (from-to)472-479
Number of pages8
JournalJournal of Infection and Chemotherapy
Volume19
Issue number3
DOIs
Publication statusPublished - 2013 Jun

Fingerprint

Streptococcus pneumoniae
Multicenter Studies
Pneumonia
Clinical Trials
Levofloxacin
Penicillin G
Quinolones
Sputum
sitafloxacin
Mutation
Antigens

Keywords

  • Gyrase
  • Levofloxacin-resistant Streptococcus pneumoniae
  • Sitafloxacin STFX)
  • Topoisomerase IV

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae : Nested cohort within a multicenter clinical trial. / Fujita, Jiro; Niki, Yoshihito; Kadota, Jun Ichi; Yanagihara, Katsunori; Kaku, Mitsuo; Watanabe, Akira; Aoki, Nobuki; Hori, Seiji; Tanigawara, Yusuke; Cash, Haley L.; Kohno, Shigeru.

In: Journal of Infection and Chemotherapy, Vol. 19, No. 3, 06.2013, p. 472-479.

Research output: Contribution to journalArticle

Fujita, Jiro ; Niki, Yoshihito ; Kadota, Jun Ichi ; Yanagihara, Katsunori ; Kaku, Mitsuo ; Watanabe, Akira ; Aoki, Nobuki ; Hori, Seiji ; Tanigawara, Yusuke ; Cash, Haley L. ; Kohno, Shigeru. / Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae : Nested cohort within a multicenter clinical trial. In: Journal of Infection and Chemotherapy. 2013 ; Vol. 19, No. 3. pp. 472-479.
@article{b9f1f0da7d84403b88dfb3c3763e2bb3,
title = "Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: Nested cohort within a multicenter clinical trial",
abstract = "We evaluated the clinical and bacteriological efficacy of oral sitafloxacin (STFX) in clinically diagnosed community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. Additionally, we cultured these patient samples to test the minimal inhibitory concentrations (MICs) of levofloxacin (LVFX), moxifloxacin (MFLX), STFX, and penicillin G (PCG), as well as identified mutations in the quinolone resistance determinant regions (QRDRs) in LVFX-resistant strains. This study is a nested cohort from a prospective, multicenter clinical trial consisting of 139 patients with community-acquired pneumonia (CAP), from which 72 were included in this study. After diagnosis of CAP caused by S. pneumoniae, STFX (50 mg twice daily, or 100 mg once daily) was orally administered for 7 days. Sixty-five patient sputum samples were then cultured for MIC analysis. In a LVFX-resistant strain that was identified, mutations in the QRDRs of the gyrA, gyrB, parC, and parE genes were examined. Of 72 patients eligible for this study, S. pneumoniae was successfully cultured from the sputum of 65 patients, and only 7 patients were diagnosed by urinary antigen only. Clinical improvement of CAP was obtained in 65 of the 69 clinically evaluable patients (65/69, 94.2 {\%}). Eradication of S. pneumoniae was observed in 62 patients of the 65 bacteriologically evaluable patients (62/65, 95.4 {\%}). Additionally, STFX showed the lowest MIC distribution compared with LVFX, MFLX, and PCG, and no major adverse reactions were observed. STFX treatment in patients with CAP caused by S. pneumoniae was found to be highly effective both clinically (94.2 {\%}) and bacteriologically (95.4 {\%}).",
keywords = "Gyrase, Levofloxacin-resistant Streptococcus pneumoniae, Sitafloxacin STFX), Topoisomerase IV",
author = "Jiro Fujita and Yoshihito Niki and Kadota, {Jun Ichi} and Katsunori Yanagihara and Mitsuo Kaku and Akira Watanabe and Nobuki Aoki and Seiji Hori and Yusuke Tanigawara and Cash, {Haley L.} and Shigeru Kohno",
year = "2013",
month = "6",
doi = "10.1007/s10156-012-0514-4",
language = "English",
volume = "19",
pages = "472--479",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae

T2 - Nested cohort within a multicenter clinical trial

AU - Fujita, Jiro

AU - Niki, Yoshihito

AU - Kadota, Jun Ichi

AU - Yanagihara, Katsunori

AU - Kaku, Mitsuo

AU - Watanabe, Akira

AU - Aoki, Nobuki

AU - Hori, Seiji

AU - Tanigawara, Yusuke

AU - Cash, Haley L.

AU - Kohno, Shigeru

PY - 2013/6

Y1 - 2013/6

N2 - We evaluated the clinical and bacteriological efficacy of oral sitafloxacin (STFX) in clinically diagnosed community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. Additionally, we cultured these patient samples to test the minimal inhibitory concentrations (MICs) of levofloxacin (LVFX), moxifloxacin (MFLX), STFX, and penicillin G (PCG), as well as identified mutations in the quinolone resistance determinant regions (QRDRs) in LVFX-resistant strains. This study is a nested cohort from a prospective, multicenter clinical trial consisting of 139 patients with community-acquired pneumonia (CAP), from which 72 were included in this study. After diagnosis of CAP caused by S. pneumoniae, STFX (50 mg twice daily, or 100 mg once daily) was orally administered for 7 days. Sixty-five patient sputum samples were then cultured for MIC analysis. In a LVFX-resistant strain that was identified, mutations in the QRDRs of the gyrA, gyrB, parC, and parE genes were examined. Of 72 patients eligible for this study, S. pneumoniae was successfully cultured from the sputum of 65 patients, and only 7 patients were diagnosed by urinary antigen only. Clinical improvement of CAP was obtained in 65 of the 69 clinically evaluable patients (65/69, 94.2 %). Eradication of S. pneumoniae was observed in 62 patients of the 65 bacteriologically evaluable patients (62/65, 95.4 %). Additionally, STFX showed the lowest MIC distribution compared with LVFX, MFLX, and PCG, and no major adverse reactions were observed. STFX treatment in patients with CAP caused by S. pneumoniae was found to be highly effective both clinically (94.2 %) and bacteriologically (95.4 %).

AB - We evaluated the clinical and bacteriological efficacy of oral sitafloxacin (STFX) in clinically diagnosed community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. Additionally, we cultured these patient samples to test the minimal inhibitory concentrations (MICs) of levofloxacin (LVFX), moxifloxacin (MFLX), STFX, and penicillin G (PCG), as well as identified mutations in the quinolone resistance determinant regions (QRDRs) in LVFX-resistant strains. This study is a nested cohort from a prospective, multicenter clinical trial consisting of 139 patients with community-acquired pneumonia (CAP), from which 72 were included in this study. After diagnosis of CAP caused by S. pneumoniae, STFX (50 mg twice daily, or 100 mg once daily) was orally administered for 7 days. Sixty-five patient sputum samples were then cultured for MIC analysis. In a LVFX-resistant strain that was identified, mutations in the QRDRs of the gyrA, gyrB, parC, and parE genes were examined. Of 72 patients eligible for this study, S. pneumoniae was successfully cultured from the sputum of 65 patients, and only 7 patients were diagnosed by urinary antigen only. Clinical improvement of CAP was obtained in 65 of the 69 clinically evaluable patients (65/69, 94.2 %). Eradication of S. pneumoniae was observed in 62 patients of the 65 bacteriologically evaluable patients (62/65, 95.4 %). Additionally, STFX showed the lowest MIC distribution compared with LVFX, MFLX, and PCG, and no major adverse reactions were observed. STFX treatment in patients with CAP caused by S. pneumoniae was found to be highly effective both clinically (94.2 %) and bacteriologically (95.4 %).

KW - Gyrase

KW - Levofloxacin-resistant Streptococcus pneumoniae

KW - Sitafloxacin STFX)

KW - Topoisomerase IV

UR - http://www.scopus.com/inward/record.url?scp=84879240218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879240218&partnerID=8YFLogxK

U2 - 10.1007/s10156-012-0514-4

DO - 10.1007/s10156-012-0514-4

M3 - Article

C2 - 23179958

AN - SCOPUS:84879240218

VL - 19

SP - 472

EP - 479

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 3

ER -